Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus PIPERACILLIN.
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus PIPERACILLIN.
AMPICILLIN TRIHYDRATE vs PIPERACILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
3.375 g IV every 6 hours (piperacillin-tazobactam); for piperacillin alone, 3 g IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
Clinical Note
moderatePiperacillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Piperacillin."
Clinical Note
moderatePiperacillin + Mycophenolic acid
"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Piperacillin resulting in a loss in efficacy."
Clinical Note
moderatePiperacillin + Plicamycin
"The serum concentration of Plicamycin can be decreased when it is combined with Piperacillin."
Clinical Note
moderate0.6-1.2 hours in adults with normal renal function; prolonged to 2-6 hours in renal impairment (CrCl <20 mL/min); requires dose adjustment in renal failure
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Renal: approximately 70-90% unchanged via glomerular filtration and tubular secretion; biliary: 10-20% excreted unchanged in bile; fecal: minor (<5%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic
Piperacillin + Valrubicin
"The serum concentration of Valrubicin can be decreased when it is combined with Piperacillin."